Clinical Trial Update: Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus [Phase 3]

View source ↗

Summary

This entry describes a Phase 3 clinical trial evaluating ganciclovir gel 0.3% for adenoviral conjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoviral Conjunctivitis
• Conjunctivitis

Drugs mentioned

• Ganciclovir Gel 0.3% (ganciclovir)

Snippet

Sponsor: Adapt Produtos Oftalmológicos Ltda. | Conditions: Conjunctivitis, Adenovirus. | Phase 3 | Status: UNKNOWN